Mersana Therapeutics, Inc. (MRSN)
NASDAQ: MRSN · Real-Time Price · USD
27.43
0.00 (0.00%)
Dec 2, 2025, 11:45 AM EST - Market open
Mersana Therapeutics Revenue
Mersana Therapeutics had revenue of $11.01M in the quarter ending September 30, 2025, a decrease of -12.61%. This brings the company's revenue in the last twelve months to $33.18M, down -4.76% year-over-year. In the year 2024, Mersana Therapeutics had annual revenue of $40.50M with 9.88% growth.
Revenue (ttm)
$33.18M
Revenue Growth
-4.76%
P/S Ratio
4.11
Revenue / Employee
$325,294
Employees
102
Market Cap
137.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 40.50M | 3.64M | 9.88% |
| Dec 31, 2023 | 36.86M | 10.27M | 38.65% |
| Dec 31, 2022 | 26.58M | 26.54M | 61,716.28% |
| Dec 31, 2021 | 43.00K | -785.00K | -94.81% |
| Dec 31, 2020 | 828.00K | -41.30M | -98.03% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MRSN News
- 15 days ago - Mersana Therapeutics Investor Alert By The Former Attorney General Of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Mersana Therapeutics, Inc. - MRSN - Business Wire
- 18 days ago - Mersana Therapeutics, Inc. (MRSN) M&A Call Transcript - Seeking Alpha
- 19 days ago - Day One Biopharma Expands Oncology Pipeline With $285 Million Mersana Buyout - Benzinga
- 19 days ago - Day One Biopharmaceuticals to Acquire Mersana Therapeutics - GlobeNewsWire
- 22 days ago - Mersana Therapeutics to Host Third Quarter 2025 Conference Call on November 14, 2025 - GlobeNewsWire
- 3 months ago - Mersana Therapeutics, Inc. (MRSN) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Mersana Therapeutics Provides Business Update and Announces Second Quarter 2025 Financial Results - GlobeNewsWire
- 4 months ago - Mersana Therapeutics to Host Second Quarter 2025 Conference Call on August 13, 2025 - GlobeNewsWire